# Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

> **NCT05116813** · PHASE2,PHASE3 · TERMINATED · sponsor: **Addex Pharma S.A.** · enrollment: 17 (actual)

## Conditions studied

- Parkinson Disease
- Dyskinesia, Drug-Induced
- Dyskinesias

## Interventions

- **DRUG:** Dipraglurant

## Key facts

- **NCT ID:** NCT05116813
- **Lead sponsor:** Addex Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-25
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-08-15
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Terminated prior to completing enrollment goals due to COVID-related difficulties in recruiting patients
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116813, "Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05116813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*